Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation.

Radujkovic A, Kordelas L, Krzykalla J, Benner A, Schult D, Majer-Lauterbach J, Beelen DW, Müller-Tidow C, Kasperk C, Dreger P, Luft T.

Haematologica. 2019 Jul 11. pii: haematol.2019.220293. doi: 10.3324/haematol.2019.220293. [Epub ahead of print]

2.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
3.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y.

Biol Blood Marrow Transplant. 2019 Jul 1. pii: S1083-8791(19)30412-4. doi: 10.1016/j.bbmt.2019.06.028. [Epub ahead of print]

PMID:
31271884
4.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Feb 7. pii: haematol.2018.205211. doi: 10.3324/haematol.2018.205211. [Epub ahead of print]

5.

Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.

Radujkovic A, Dai H, Kordelas L, Beelen D, Rachakonda SP, Müller-Tidow C, Kumar R, Dreger P, Luft T.

Haematologica. 2019 Apr;104(4):827-834. doi: 10.3324/haematol.2018.202267. Epub 2018 Dec 4.

6.

A prospective study on serum Cytokeratin (CK)-18 and CK18 fragments as biomarkers of acute hepato-intestinal GVHD.

Sauer S, Hüsing J, Hajda J, Neumann F, Radujkovic A, Ho AD, Dreger P, Luft T.

Leukemia. 2018 Dec;32(12):2685-2692. doi: 10.1038/s41375-018-0183-0. Epub 2018 Jun 27.

PMID:
29950693
7.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

8.

Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.

Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, Müller-Tidow C, Kumar R, Dreger P, Luft T.

J Clin Oncol. 2018 Mar 10;36(8):789-800. doi: 10.1200/JCO.2017.76.4662. Epub 2018 Jan 25.

PMID:
29369699
9.

Haploidentical transplant in patients with myelodysplastic syndrome.

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N.

Blood Adv. 2017 Sep 27;1(22):1876-1883. doi: 10.1182/bloodadvances.2017007146. eCollection 2017 Oct 10.

10.

Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies.

Radujkovic A, Kordelas L, Krzykalla J, Beelen DW, Benner A, Lehners N, Schmidt K, Dreger P, Luft T.

J Clin Oncol. 2017 Sep 20;35(27):3143-3152. doi: 10.1200/JCO.2017.73.0085. Epub 2017 Aug 3.

PMID:
28771378
11.

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.

Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, Sandmaier BM, Becker N, Radujkovic A, Dreger P, Penack O.

Lancet Haematol. 2017 Sep;4(9):e414-e423. doi: 10.1016/S2352-3026(17)30108-4. Epub 2017 Jul 18.

PMID:
28733186
12.

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, Ho AD, Zeier M, Dreger P, Luft T.

Bone Marrow Transplant. 2017 Oct;52(10):1399-1405. doi: 10.1038/bmt.2017.119. Epub 2017 Jun 26.

PMID:
28650448
13.

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.

Radujkovic A, Dietrich S, Andrulis M, Benner A, Longerich T, Pellagatti A, Nanda K, Giese T, Germing U, Baldus S, Boultwood J, Ho AD, Dreger P, Luft T.

Int J Cancer. 2016 Sep 15;139(6):1402-13. doi: 10.1002/ijc.30181. Epub 2016 Jun 3.

14.

Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.

Radujkovic A, Schnitzler P, Ho AD, Dreger P, Luft T.

Clin Nutr. 2017 Apr;36(2):542-551. doi: 10.1016/j.clnu.2016.01.021. Epub 2016 Feb 10.

PMID:
26899917
15.

Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome.

Radujkovic A, Becker N, Benner A, Penack O, Platzbecker U, Stölzel F, Bornhäuser M, Hegenbart U, Ho AD, Dreger P, Luft T.

Oncotarget. 2015 Oct 27;6(33):35095-106. doi: 10.18632/oncotarget.4805.

16.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.

17.

Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation.

Dietrich S, Radujkovic A, Stölzel F, Falk CS, Benner A, Schaich M, Bornhäuser M, Ehninger G, Krämer A, Hegenbart U, Ho AD, Dreger P, Luft T.

Transplantation. 2015 May;99(5):1065-71. doi: 10.1097/TP.0000000000000471.

PMID:
25340610
18.

Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease.

Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A, Isermann B, Ho AD, Uharek L, Dreger P, Kumar R, Luft T.

J Clin Oncol. 2014 Oct 20;32(30):3421-7. doi: 10.1200/JCO.2013.54.4056. Epub 2014 Sep 15.

PMID:
25225421
19.

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.

Radujkovic A, Luft T, Dreger P, Ho AD, Jens Zeller W, Fruehauf S, Topaly J.

Cancer Chemother Pharmacol. 2014 Aug;74(2):427-32. doi: 10.1007/s00280-014-2533-6. Epub 2014 Jul 20.

PMID:
25038611
20.

Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.

Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F.

Leuk Lymphoma. 2014 Dec;55(12):2967-9. doi: 10.3109/10428194.2014.911862. Epub 2014 Jun 16. No abstract available.

PMID:
24707945
21.

Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.

Radujkovic A, Dietrich S, Bochtler T, Krämer A, Schöning T, Ho AD, Dreger P, Luft T.

Eur J Haematol. 2014 Aug;93(2):112-7. doi: 10.1111/ejh.12308. Epub 2014 Apr 3.

PMID:
24628527
22.

Imatinib-supplemented myeloablative total-body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia.

Radujkovic A, Dreger P, Hegenbart U, Buss EC, Luft T, Ho AD, Fruehauf S, Topaly J.

Eur J Haematol. 2014 Jun;92(6):546-9. doi: 10.1111/ejh.12289. Epub 2014 Mar 15. No abstract available.

PMID:
24527710
23.

Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.

Dietrich S, Weidle J, Rieger M, Meissner J, Radujkovic A, Ho AD, Dreger P, Witzens-Harig M.

Leukemia. 2014 Mar;28(3):708-9. doi: 10.1038/leu.2013.332. Epub 2013 Nov 12. No abstract available.

PMID:
24217198
24.

High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.

Dietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S, Radujkovic A, Hegenbart U, Ho AD, Dreger P, Luft T.

Haematologica. 2014 Mar;99(3):541-7. doi: 10.3324/haematol.2013.090209. Epub 2013 Oct 18.

25.

Charcot-Leyden crystals and bone marrow necrosis in acute myeloid leukemia.

Radujkovic A, Bellos F, Andrulis M, Ho AD, Hundemer M.

Eur J Haematol. 2011 May;86(5):451-2. doi: 10.1111/j.1600-0609.2011.01594.x. Epub 2011 Mar 30. No abstract available.

PMID:
21342270
26.

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells.

Radujkovic A, Fruehauf S, Zeller WJ, Ho AD, Topaly J.

Cancer Chemother Pharmacol. 2010 Jul;66(2):255-64. doi: 10.1007/s00280-009-1158-7. Epub 2009 Oct 28.

PMID:
19862526
27.

Normal-tissue radioprotection by overexpression of the copper-zinc and manganese superoxide dismutase genes.

Veldwijk MR, Herskind C, Sellner L, Radujkovic A, Laufs S, Fruehauf S, Zeller WJ, Wenz F.

Strahlenther Onkol. 2009 Aug;185(8):517-23. doi: 10.1007/s00066-009-1973-0. Epub 2009 Aug 4.

PMID:
19652935
28.
29.

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ.

Leukemia. 2005 Jul;19(7):1198-206.

PMID:
15902298

Supplemental Content

Loading ...
Support Center